REGN Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals is a biotechnology company known for breakthrough therapies including Dupixent (atopic dermatitis), Eylea (macular degeneration), and a growing pipeline in oncology and rare diseases. Sector: Healthcare.

Regeneron Pharmaceuticals Inc (REGN) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

Examining the company through a capital allocation lens, ROIC is 12.16%, WACC is 6.31%, and the economic spread is 5.85%. On balance, the company is generating returns above their cost of capital, though the margin is slim enough to warrant attention. Supporting metrics show ROE at 14.90% and ROA at 8.76%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company that is value-creative but with less room for execution slippage.

Valuation currently screens at trailing P/E of 18.35, forward P/E of 16.79, PEG of 43.84. Trailing and forward P/E are close together, implying the market does not expect a significant change in the earnings trajectory over the near term. At this PEG level, the company is priced generously relative to its expected earnings trajectory — execution risk is meaningfully priced in. The aggregate current ratio of 4.13 reflects a company with strong liquidity buffers against short-term stress. The valuation profile here is neither obviously cheap nor dramatically expensive — a setup where the return case is built more on earnings delivery than on re-rating potential.

From gross to free cash flow, gross margin sits at 64.96%, operating margin at 25.81%, and free cash flow margin at 27.35%. At this level, gross margins reflect the kind of pricing power and cost insulation that characterizes category-leading businesses. The operating margin reading is healthy — adequate to support reinvestment without sacrificing profitability. At this level, FCF margins reflect a company with genuine capital efficiency and strong cash-based earnings quality. Taken together, this margin profile points to a company with durable economics and dependable cash generation capacity.

Revenue momentum and analyst targets together paint a picture where the estimated 12-month price change of 7.96%, where target-based return potential appears limited without multiple expansion, while TTM revenue growth of 2.51% indicating muted but still positive top-line momentum across the company. Reported revenue growth is the operational foundation; the analyst target spread shows what the market is willing to pay above it — and that premium can evaporate quickly if delivery slips. For investors, the central question is whether the operating momentum visible in revenues is durable enough to support the price appreciation implied by consensus targets. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

The composite read is moderately constructive but uneven — in the absence of a clear catalyst, a neutral stance is well-supported by the data.

This summary is based on publicly available quantitative data and is not intended as investment advice. Carefully consider your personal financial circumstances before making any decisions.